FDA litargirio warning
This article was originally published in The Rose Sheet
Executive Summary
Consumers should immediately stop all use of litargirio powder, which is commonly found in deodorant, foot fungicide and burn and wound treatment products, agency announces. FDA is working with the Consumer Product Safety Commission to alert public to risks of lead poisoning after ingestion or contact with skin. Powder is a traditional remedy popular in the Dominican Republic that does not have any proven health benefits and is particularly harmful to children, agency points out. Rhode Island Department of Health alerted FDA to product's dangers after several children using litargirio as deodorant were treated for lead poisoning...
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.